Bristol-Myers Squibb Co
(LTS:0R1F)
$
54.48
-1.095 (-1.97%)
Market Cap: 109.81 Bil
Enterprise Value: 153.11 Bil
PE Ratio: 0
PB Ratio: 6.41
GF Score: 84/100 Bristol-Myers Squibb Co at Citi BioPharma Conference Transcript
Sep 08, 2022 / 12:50PM GMT
Release Date Price:
$68.49
(+0.40%)
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
[Welcome] to the Bristol-Myers session. So delighted to introduce our guests from Bristol-Myers Squibb today. We have Adam Lenkowsky, who's Head of U.S. Commercialization. We've got Roland Chen, who is Head of Cardiovascular Development at Bristol-Myers. We've also got Tim Powers in the audience, who's Head of IR. So thank you all for joining us today.
Adam Lenkowsky
Bristol-Myers Squibb Company - Head of U.S. Oncology
Thanks for having us.
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
My pleasure. So maybe to start with milvexian segue to [dacarabasitenib], and then we'll ramp up the rest of it in the second half of the conversation. If anyone in the room has a question, then please don't be shy, raise a hand, and we're happy to take your question.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot